CELLECTIS SA Extends Its TAL Technology Intellectual Property Portfolio Through the Acquisition of Two Exclusive Licenses From Iowa State University  
10/25/2012 10:07:40 AM

PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Alternext: ALCLS), the genome engineering specialist, announces that it has signed two exclusive license agreements with the Iowa State University that grant Cellectis the worldwide right to use inventions related to TAL effector-nucleases (TALENsTM) and monomeric TALENsTM.